Low Pro-Brain Natriuretic Peptide Levels Predict Benign Clinical Outcome in Acute Pulmonary Embolism

DOI Web Site 被引用文献4件
  • Nils Kucher
    From the Swiss Cardiovascular Center, Cardiology (N.K., S.W., B.M., O.M.H.), the Department of Clinical Chemistry (G.P.), and the Department of Radiology (T.D.), University Hospital, Bern, Switzerland.
  • Gert Printzen
    From the Swiss Cardiovascular Center, Cardiology (N.K., S.W., B.M., O.M.H.), the Department of Clinical Chemistry (G.P.), and the Department of Radiology (T.D.), University Hospital, Bern, Switzerland.
  • Tanja Doernhoefer
    From the Swiss Cardiovascular Center, Cardiology (N.K., S.W., B.M., O.M.H.), the Department of Clinical Chemistry (G.P.), and the Department of Radiology (T.D.), University Hospital, Bern, Switzerland.
  • Stephan Windecker
    From the Swiss Cardiovascular Center, Cardiology (N.K., S.W., B.M., O.M.H.), the Department of Clinical Chemistry (G.P.), and the Department of Radiology (T.D.), University Hospital, Bern, Switzerland.
  • Bernhard Meier
    From the Swiss Cardiovascular Center, Cardiology (N.K., S.W., B.M., O.M.H.), the Department of Clinical Chemistry (G.P.), and the Department of Radiology (T.D.), University Hospital, Bern, Switzerland.
  • Otto Martin Hess
    From the Swiss Cardiovascular Center, Cardiology (N.K., S.W., B.M., O.M.H.), the Department of Clinical Chemistry (G.P.), and the Department of Radiology (T.D.), University Hospital, Bern, Switzerland.

書誌事項

公開日
2003-04
DOI
  • 10.1161/01.cir.0000064898.51892.09
公開者
Ovid Technologies (Wolters Kluwer Health)

この論文をさがす

説明

<jats:p> <jats:bold> <jats:italic>Background—</jats:italic> </jats:bold> The role of pro-brain natriuretic peptide (proBNP) for the prediction of clinical outcome has not been examined in patients with acute pulmonary embolism (PE). </jats:p> <jats:p> <jats:bold> <jats:italic>Methods and Results—</jats:italic> </jats:bold> ProBNP levels were measured in 73 patients with acute PE within 4 hours of admission. Adverse clinical outcome was defined as in-hospital death or the need for at least 1 of the following: cardiopulmonary resuscitation, mechanical ventilation, pressors, thrombolysis, catheter fragmentation, or surgical embolectomy. In the 53 patients with a benign clinical outcome, proBNP (median 121, range 16 to 34 802 pg/mL) was lower than in 20 patients with adverse clinical outcome (median 4250, range 92 to 49 607 pg/mL; <jats:italic>P</jats:italic> <0.0001). The negative predictive value of proBNP levels <500 pg/mL to predict adverse clinical outcome was 97% (95% confidence interval 84 to 99). ProBNP remained an independent predictor for adverse clinical outcome (odds ratio 14.6; 95% confidence interval 1.5 to 139.0; <jats:italic>P</jats:italic> =0.02) after adjusting for severity of PE (submassive/massive), troponin T levels >0.01ng/mL, age >70 years, gender, and history of congestive heart failure. </jats:p> <jats:p> <jats:bold> <jats:italic>Conclusions—</jats:italic> </jats:bold> Low proBNP levels predict an uneventful hospital course in patients with acute PE. A proBNP level <500 pg/mL identifies patients who will be potential candidates for an abbreviated hospital length of stay or care on a completely outpatient basis. </jats:p>

収録刊行物

  • Circulation

    Circulation 107 (12), 1576-1578, 2003-04

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (4)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ